Dedicated to transforming the lives of patients with severe and other genetic diseases through innovative gene therapy.
Stem cell technology β’ Gene therapy β’ Orphan diseases β’ Paediatric diseases
201 - 500
π° $150M Post-IPO Equity on 2021-02